Auroryx

Country of origin - Switzerland
Pharm-Group - Antidepressants - reversible MAO inhibitors

Manufacturers - Hoffmann-La Roche (Switzerland)
International name - Moclobemide
Dosage forms - film-coated tablets 100 mg, film-coated tablets 150 mg
Composition - Active ingredient - Moclobemide.

Indications for use - Depression of various etiologies: with manic-depressive psychosis, various forms of schizophrenia, chronic alcoholism, senile and involutional, reactive and neurotic, social phobia.

Contraindications - Hypersensitivity, acute impairment of consciousness, simultaneous use of selegiline, pregnancy, breastfeeding (stop during treatment), childhood (safety and effectiveness of use in children have not been determined).

Side effects - From the nervous system and sensory organs: dizziness, headache, sleep disturbance, agitation, anxiety, irritability, confusion, paresthesia, blurred vision. From the gastrointestinal tract: dry mouth, nausea, heartburn, feeling of fullness, diarrhea/constipation. Other: skin reactions (rash, itching, urticaria, hot flashes).

Interaction - Strengthens and prolongs the effect of sympathomimetics and opiates. Increases the likelihood of developing adverse reactions from the central nervous system when combined with clomipramine, dextromethorphan. Cimetidine slows down the biotransformation of moclobemide.

Overdose - No data available.

Special instructions - Prescribe with caution for thyrotoxicosis and pheochromocytoma (hypertensive reactions may develop). Not recommended for patients in whom agitation is the main clinical manifestation of the disease. In case of schizophrenic or schizoaffective psychosis, an increase in schizophrenic symptoms is possible (in this case it is necessary to switch to antipsychotics). Patients with high blood pressure should avoid excessive consumption of foods containing tyramine.

Literature - Encyclopedia of Medicines 2004